Food and Drug Administration (FDA) Podcasts 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - July 17, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: SFDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
On April 9, 2019 FDA announced we have received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - April 17, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)
(Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
On February 25, 2019 FDA alerted the public that a safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib (brand names Xeljanz, Xeljanz XR) was used in patients with rheumatoid arthritis (or RA). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - March 5, 2019 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
